Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Invested Capital (2016 - 2025)

Historic Invested Capital for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $22.0 million.

  • Lineage Cell Therapeutics' Invested Capital fell 6598.45% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year decrease of 6598.45%. This contributed to the annual value of $78.4 million for FY2024, which is 2359.23% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Invested Capital is $22.0 million, which was down 6598.45% from $48.4 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Invested Capital's 5-year high stood at $124.7 million during Q2 2021, with a 5-year trough of $22.0 million in Q3 2025.
  • For the 5-year period, Lineage Cell Therapeutics' Invested Capital averaged around $77.7 million, with its median value being $73.5 million (2022).
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 3223.2% in 2021, then crashed by 6598.45% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Invested Capital (Quarter) stood at $92.3 million in 2021, then dropped by 20.38% to $73.5 million in 2022, then dropped by 13.66% to $63.4 million in 2023, then increased by 23.59% to $78.4 million in 2024, then tumbled by 71.88% to $22.0 million in 2025.
  • Its Invested Capital stands at $22.0 million for Q3 2025, versus $48.4 million for Q2 2025 and $79.0 million for Q1 2025.